1. Liu SH, Chu HI (1942) Treatment of renal osteodystrophy with dihydrotachysterol (A.T.10) and iron. Science 95(2467):388–389
2. Moe S, Drueke T, Cunningham J, Goodman W, Martin K, Olgaard K et al (2006) Definition, evaluation, and classification of renal osteodystrophy: a position statement from kidney disease: improving global outcomes (KDIGO). Kidney Int 69(11):1945–1953
3. Coen G, Ballanti P, Bonucci E, Calabria S, Centorrino M, Fassino V et al (1998) Bone markers in the diagnosis of low turnover osteodystrophy in haemodialysis patients. Nephrol Dial Transplant Off Publ Eur Dial Transplant Assoc Eur Ren Assoc 13(9):2294–2302
4. Ott SM (2008) Histomorphometric measurements of bone turnover, mineralization, and volume. Clin J Am Soc Nephrol 3(Suppl 3):S151–S156
5. Koos R, Brandenburg V, Mahnken AH, Schneider R, Dohmen G, Autschbach R et al (2013) Sclerostin as a potential novel biomarker for aortic valve calcification: an in-vivo and ex-vivo study. J Heart Valve Dis 22(3):317–325